دورية أكاديمية
Autism Spectrum Disorder and Complementary-Integrative Medicine.
| العنوان: | Autism Spectrum Disorder and Complementary-Integrative Medicine. |
|---|---|
| المؤلفون: | Vandana P; Division of Child & Adolescent Psychiatry, Columbia University Valegos College of Physicians and Surgeons, Center for Autism and the Developing Brain, 21 Bloomingdale Road, White Plains, NY 10605, USA. Electronic address: pv2359@cumc.columbia.edu., Simkin DR; Department of Psychiatry, Emory University School of Medicine., Hendren RL; University of California San Francisco, Pritzker Building, 675 18th Street, San Francisco, CA 94143-3132, USA., Arnold LE; Department of Psychiatry and Behavioral Health, Ohio State University, McCampbell 395E, 1581 Dodd Drive, Columbus, OH 43210, USA. |
| المصدر: | Child and adolescent psychiatric clinics of North America [Child Adolesc Psychiatr Clin N Am] 2023 Apr; Vol. 32 (2), pp. 469-494. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Health Country of Publication: United States NLM ID: 9313451 Publication Model: Print Cited Medium: Internet ISSN: 1558-0490 (Electronic) Linking ISSN: 10564993 NLM ISO Abbreviation: Child Adolesc Psychiatr Clin N Am Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Philadelphia : Elsevier Health Original Publication: Philadelphia : W.B. Saunders Co., c1992- |
| مواضيع طبية MeSH: | Autism Spectrum Disorder*/drug therapy , Integrative Medicine* , Autistic Disorder*, Child ; Humans ; Quality of Life ; Risperidone/therapeutic use |
| مستخلص: | Autism spectrum disorder (ASD) is a neurodevelopmental disorder that affects 0.6%-1.7% of children. The etiology of autism is hypothesized to include both biological and environmental factors (Watts, 2008). In addition to the core symptoms of social-communication delay and restricted, repetitive interests, co-occurring irritability/aggression, hyperactivity, and insomnia negatively impact adaptive functioning and quality of life of patients and families. Despite years of effort, no pharmacologic agent has been found that targets the core symptoms of ASD. The only FDA-approved agents are risperidone and aripiprazole for agitation and irritability in ASD, not for core symptoms. Though they effectively reduce irritability/violence, they do so at the expense of problematic side effects: metabolic syndrome, elevated liver enzymes, and extrapyramidal side effects. Thus, it is not surprising that many families of children with ASD turn to nonallopathic treatment, including dietary interventions, vitamins, and immunomodulatory agents subsumed under complementary-integrative medicine (CIM). Per recent studies, 27% to 88% of families report using a CIM treatment. In an extensive population-based survey of CIM, families of children with more severe ASD, comorbid irritability, GI symptoms, food allergies, seizures, and higher parental education tend to use CIM at higher rates. The perceived safety of CIM treatments as "natural treatment" over allopathic medication increases parental comfort in using these agents. The most frequently used CIM treatments include multivitamins, an elimination diet, and Methyl B12 injections. Those perceived most effective are sensory integration, melatonin, and antifungals. Practitioners working with these families should improve their knowledge about CIM as parents currently perceive little interest in and poor knowledge of CIM by physicians. This article reviews the most popular complementary treatments preferred by families with children with autism. With many of them having limited or poor quality data, clinical recommendations about the efficacy and safety of each treatment are discussed using the SECS versus RUDE criteria. Competing Interests: Disclosure Dr L.E. Arnold has received research funding from Supernus Pharmaceuticals, Roche/Genentech Pharmaceuticals, Otsuka Pharmaceuticals, Axial Yamo, and Young Living Essential Oils and the National Institutes of Health (USA, R01 MH 100144), has consulted with Pfizer Pharmaceuticals and CHADD, and been on advisory boards for Otsuka and Roche/Genentech. Dr R.L. Hendren has recent research grants from Curemark, Roche, Otsuka, GW LTD, and Axial Biotherapeutics; is on Advisory Boards for BioMarin, Axial Bio Therapeutics, and Janssen. Dr P. Vandana has no financial disclosures. Dr D.R. Simkins has no financial disclosures. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Autism treatment; Essential fatty acids; Vitamins/minerals/diet |
| المشرفين على المادة: | L6UH7ZF8HC (Risperidone) |
| تواريخ الأحداث: | Date Created: 20230505 Date Completed: 20230508 Latest Revision: 20230510 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.chc.2022.08.004 |
| PMID: | 37147047 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1558-0490 |
|---|---|
| DOI: | 10.1016/j.chc.2022.08.004 |